Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx
MELBOURNE, Australia, and INDIANAPOLIS, Ind., July 21, 2026 Telix Pharmaceuticals announced that the first patient has been dosed in...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
MELBOURNE, Australia, and INDIANAPOLIS, Ind., July 21, 2026 Telix Pharmaceuticals announced that the first patient has been dosed in...
Melbourne, Australia and Indianapolis, IN, United States – May 5, 2026 Telix Pharmaceuticals Limited has announced the publication of...
